Tandem Diabetes Care (Nasdaq:TNDM) stock is on the rise following strong third-quarter financial results from the insulin pump maker.
Our sister site, Drug Delivery Business News, reports today that the company topped Wall Street forecasts and raised its full-year guidance following another quarter of growth. As a result, shares of TNDM rose 5% to $35.85 apiece in post-market trading today.
Key metrics from the company’s earnings report included a 29.5% bottom-line gain on a sales increase of 31.4%. The company also reported pump shipment growth totaling more than 25% compared to the same period a year ago.
Tandem also completed a clinical study in support of a regulatory filing to expand the indication for its Control-IQ automated insulin dosing technology to include people with type 2 diabetes.
Get the full story at our sister site, Drug Delivery Business News.
